Saudi Pharmaceutical Journal, 2022 Background: This review aimed to conduct an indirect comparison using a Bayesian network meta-analysis of randomized controlled trials (RCTs) to compare the efficacy and safety of delafloxacin versus other single antibiotic regimens for the empiric ...
Abdullah A. Alhifany +10 more
doaj +1 more source
Journal of Global Antimicrobial Resistance, 2020 Objectives: Delafloxacin is a broad-spectrum anionic fluoroquinolone with activity against Gram-positive and Gram-negative organisms, including methicillin-resistant Staphylococcus aureus.
Dee Shortridge +3 more
doaj +1 more source
Manuka-type honeys can eradicate biofilms produced by Staphylococcus aureus strains with different biofilm-forming abilities [PDF]
, 2014 Chronic wounds are a major global health problem. Their management is difficult and costly, and the development of antibiotic resistance by both planktonic and biofilm-associated bacteria necessitates the use of alternative wound treatments. Honey is now
Adams +58 more
core +3 more sources
A clinical pharmacological experimental research analysis of the evidence-based rational pharmacotherapeutics of pefloxacin and newer quinolones [PDF]
, 2022 Background: Pefloxacin is a newer broad-spectrum bactericidal fluoroquinolone antibiotic, with superior antibacterial activity in vivo against pathogenic ocular gram-negative and anaerobic microorganisms and better pharmacokinetic properties.Methods: 100
Hazra, Moumita
core +2 more sources
Recent Advances in Pyridine Scaffold: Focus on Chemistry, Synthesis, and Antibacterial Activities
BioMed Research International, Volume 2023, Issue 1, 2023., 2023 Multidrug‐resistant (MDR) pathogens have created a fatal problem for human health and antimicrobial treatment. Among the currently available antibiotics, many are inactive against MDR pathogens. In this context, heterocyclic compounds/drugs play a vital role. Thus, it is very much essential to explore new research to combat the issue.
Md. Badrul Islam +7 more
wiley +1 more source
Lack of phototoxicity potential with delafloxacin in healthy male and female subjects:comparison to lomefloxacin [PDF]
, 2018 Aims: Delafloxacin is a fluoroquinolone antibiotic recently approved by the FDA for treatment of acute bacterial skin and skin structure infections (ABSSSI).
Cammarata, S. +6 more
core +3 more sources
Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment [PDF]
The Journal of Clinical Pharmacology, 2016 AbstractDelafloxacin is a novel anionic fluoroquinolone with robust activity against Gram‐positive, Gram‐negative, atypical, and anaerobic bacteria, including methicillin‐resistant S aureus. Delafloxacin is currently being studied for the treatment of acute bacterial skin and skin structure infections and community‐acquired pneumonia.
Hoover, Randall +7 more
openaire +2 more sources
The In Vitro Activity of Delafloxacin and Comparator Agents Against Bacterial Pathogens Isolated From Patients With Cancer [PDF]
, 2023 BACKGROUND: Fluoroquinolones are used for infection prevention in high-risk patients with haematological malignancies. Fluoroquinolones are active against many Gram-negative bacilli (GNB) but are less active against Gram-positive organisms.
Gerges, Bahgat +5 more
core +1 more source
Correction to: Delafloxacin: First Global Approval [PDF]
Drugs, 2018 The article Delafloxacin: First Global Approval, written by Anthony Markham, was originally published Online First without open access.
openaire +2 more sources
Efficacy of Delafloxacin against the Biothreat Pathogen Burkholderia pseudomallei
Antimicrobial Agents and Chemotherapy, 2021 The in vitro activity and in vivo efficacy of delafloxacin were evaluated against the causative pathogen of melioidosis, Burkholderia pseudomallei . Delafloxacin MICs were determined by broth microdilution according to CLSI guidelines for 30 isolates of B ...
Sandra McCurdy +4 more
openaire +2 more sources